{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973724",
  "id": "02973724",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0929",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7tpn6gnkgq7.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Quarterly Report & Appendix 4C (June 2025)**  \n- **Cash Position**:  \n  - Closing cash balance: **A$0.883M** (down from A$1.709M prior quarter).  \n  - Operating cash outflow: **A$0.818M** (improved from A$0.959M prior quarter).  \n  - Unused funding facility: **A$10.78M** (from A$15M convertible note facility).  \n\n- **Key Operational Updates**:  \n  - **FDA Progress**: Positive pre-IND feedback received for MagSense\u00ae HER2 breast cancer imaging agent; IND submission expected Q3 2025.  \n  - **Phase 2 Trial Prep**: Manufacturing, CRO selection, and Principal Investigator (Dr. William Dooley) confirmed.  \n  - **Prostate Program**: Dr. Leonardo Kayat-Bittencourt appointed as clinical advisor.  \n\n- **Outlook**:  \n  - FDA response to IND anticipated Q4 2025.  \n  - Reduced R&D spend on prostate/ovarian programs due to funding constraints.  \n\n#### **No material capital markets activity (e.g., raising, halt, or significant M&A) identified.**  \n\n**Note**: Excluded routine operational/non-financial details. Focused on liquidity, clinical milestones, and regulatory catalysts.",
  "usage": {
    "prompt_tokens": 4593,
    "completion_tokens": 288,
    "total_tokens": 4881,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:40:40.875314"
}